Search Results - "Edgin, Abigail R."

Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors by Chen, Fan, Byrd, Aria L., Liu, Jinpeng, Flight, Robert M., DuCote, Tanner J., Naughton, Kassandra J., Song, Xiulong, Edgin, Abigail R., Lukyanchuk, Alexsandr, Dixon, Danielle T., Gosser, Christian M., Esoe, Dave-Preston, Jayswal, Rani D., Orkin, Stuart H., Moseley, Hunter N. B., Wang, Chi, Brainson, Christine Fillmore

“…Inhibitors of the Polycomb Repressive Complex 2 (PRC2) histone methyltransferase EZH2 are approved for certain cancers, but realizing their wider utility…”
Get full text

Dysregulated Polycomb Repressive Complex 2 contributes to chronic obstructive pulmonary disease by rewiring stem cell fate by Byrd, Aria L., Qu, Xufeng, Lukyanchuk, Alexsandr, Liu, Jinpeng, Chen, Fan, Naughton, Kassandra J., DuCote, Tanner J., Song, Xiulong, Bowman, Hannah C., Zhao, Yanming, Edgin, Abigail R., Wang, Chi, Liu, Jinze, Brainson, Christine Fillmore

“…Aberrant lung cell differentiation is a hallmark of many lung diseases including chronic obstructive pulmonary disease (COPD). The EZH2-containing Polycomb…”
Get full text

Cellular Origins of EGFR‐Driven Lung Cancer Cells Determine Sensitivity to Therapy by Chen, Fan, Liu, Jinpeng, Flight, Robert M., Naughton, Kassandra J., Lukyanchuk, Alexsandr, Edgin, Abigail R., Song, Xiulong, Zhang, Haikuo, Wong, Kwok‐Kin, Moseley, Hunter N. B., Wang, Chi, Brainson, Christine F.

“…Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKIs) is one of the major precision medicine treatment options for lung…”
Get full text